QualityDipStocks / Health Care · Pharmaceuticals
Ascendis Pharma A/S Ordinary Share ASND
Outside our quality screen, so we don’t track its dips. It’s 10% below its 52-week high.
Outside our quality screen. No fair value estimate for now: there isn’t enough data.
Worth knowing
- Revenue up 98% in a year, top 3% of the 1820 we measure
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- —
- Off 52-wk high
- −10%
- Risk vs market
- Lowbeta 0.28
4 bullish · 4 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for ASND: Capital spending isn't tagged for the latest period in SEC XBRL data. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much ASND moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Has moved mostly independently of the market, but its own price swings are 3.0× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.28
- Volatility
- 39% vs 13% SPY
- Correlation SPY
- 0.09
- Correlation QQQ
- 0.05
How it ranks
Where ASND stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Top quarter on 1 of 3 measures
- Dividends + buybacks yield0.1% · cash paid out or used to retire shares, vs market capLowest 20%of 1,836
- Revenue growth, last 12 months+98% · vs the 12 months beforeTop 2%of 1,814
- Operating margin−19% · of sales kept as operating profitLowest 4%of 1,288
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
FCF value $3.80
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
GrowthSales grew 98% to $806M over the last 12 months vs the 12 months before (SEC filings).
ProfitabilityOperating margin widened to −18.9% in FY2025 from −170.8% in FY2023 (SEC filings).
GrowthSales compounded 141% a year from FY2022 to FY2025.
ProfitabilityGross margin widened to 86.8% in FY2025 from 83.4% in FY2023 (SEC filings).
Top bearish points 4 of 5
Balance sheetOperating income covers interest only -1.7× over the last 12 months.
ProfitabilityLost $255M over the last 12 months (net income, SEC filings).
ProfitabilityLoses money at the operating line: −19% operating margin over the last 12 months.
RiskReports earnings Nov 11 (consensus EPS $1.13): results can move the price sharply and reset Market Value.
All fundamentals
Sales +98%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anot reported in its SEC filings
- FCF yield
- n/anot reported in its SEC filings
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 20.34×
- Price / book
- n/anot reported in its SEC filings
- Market cap
- $16.4Blisted
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $806M
- Sales growth, 12 months
- +98.0%vs the 12 months before
- Sales growth, 3 yrs
- +141.4%/yrfrom FY2022
- Diluted EPS, 12 months
- −$3.76
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$255M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 86.8%
- Operating margin
- −18.9%
- Net margin
- −31.7%
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- n/anegative shareholder equity
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $690M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- -1.7×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- n/anot reported in its SEC filings
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- $19M0.1% of market cap
- Share count, 1 year
- n/ano quarterly diluted share count
- Stock-based comp
- n/anot reported in its SEC filings
Trailing 12 months to Dec 31, 2025; balance sheet at Dec 31, 2025. From Ascendis Pharma A/S Ordinary Share’s SEC filings, reported in EUR and converted to US dollars. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $0.0B · Sales +115%
- Free cash flow, 12 months$0.0B
- Free-cash-flow yield0.1%
- Free-cash-flow margin1%
- Gross margin91%
- Operating margin65%
- Return on invested capital43%
- Return on equity119%
- Sales growth (latest quarter vs year-ago quarter)+115%
- Net debt / EBITDA−1.4×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $248.98
- 52-wk lowlowest close, 1 year$196.01−21.3%
- PriceMon Nov 2 close$248.98you are here
- 52-wk highhighest close, 1 year$277.18+11.3%
Momentum & 52-week range
RSI 61 · 5 days +1.6%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 11
- DateWed Nov 11
- Consensus EPS$1.13
- Year-ago EPS($1.17)
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
ASND is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Ascendis Pharma A/S Ordinary Share in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.